Hims & Hers Health (NYSE:HIMS) Stock Price Up 8.5% – Here’s What Happened

Hims & Hers Health, Inc. (NYSE:HIMS) was up 8.5% on Thursday . The company traded as high as $35.65 and last traded at $34.3880. Approximately 10,446,274 shares were traded during mid-day trading, a decline of 62% from the average daily volume of 27,624,584 shares. The stock had previously closed at $31.68.

Key Hims & Hers Health News

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: The FDA panel’s favorable peptide recommendation could eventually broaden Hims & Hers’ addressable market and support its emerging peptide therapy business. FDA Panel Narrowly Backs Four Peptides — Hims & Hers Stock in the Spotlight
• Neutral Sentiment: Truist raised its price target on HIMS to $27 from $23, but kept a hold rating, suggesting the firm sees limited upside from current levels. Tickerreport.com
• Neutral Sentiment: Recent commentary and search interest have kept HIMS in focus, reflecting elevated trading attention around the FDA-driven peptide story. Is Trending Stock Hims & Hers Health, Inc. (HIMS) a Buy Now?
• Negative Sentiment: The sharp pullback appears consistent with a sell-the-news move as traders locked in gains after the initial FDA-related spike, since the regulatory process is not finished. Why Is HIMS Stock Rallying 13% Today?
• Negative Sentiment: Insider selling and mixed hedge fund positioning may also weigh on investor sentiment, as many major holders reduced exposure in the latest quarter. Hims & Hers Health Slides as Traders Fade Peptide Rally

Wall Street Analysts Forecast Growth

A number of brokerages have commented on HIMS. BTIG Research restated a “neutral” rating on shares of Hims & Hers Health in a research note on Tuesday, May 12th. Bank of America upped their price objective on Hims & Hers Health from $36.00 to $37.00 and gave the company a “neutral” rating in a research note on Thursday, July 9th. UBS Group set a $23.00 target price on Hims & Hers Health in a report on Friday, May 22nd. Weiss Ratings downgraded Hims & Hers Health from a “hold (c)” rating to a “sell (d)” rating in a research report on Tuesday, May 12th. Finally, Wall Street Zen lowered Hims & Hers Health from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Four investment analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $31.43.

Hims & Hers Health Stock Down 14.2%

The stock has a market capitalization of $6.50 billion, a P/E ratio of -312.26, a P/E/G ratio of 92.14 and a beta of 2.35. The firm’s fifty day moving average is $30.75 and its 200-day moving average is $26.34. The company has a current ratio of 1.69, a quick ratio of 1.56 and a debt-to-equity ratio of 2.18.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings results on Monday, May 11th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.44). The firm had revenue of $608.10 million during the quarter, compared to analyst estimates of $616.84 million. Hims & Hers Health had a negative net margin of 0.56% and a positive return on equity of 6.10%. Hims & Hers Health’s quarterly revenue was up 3.8% on a year-over-year basis. During the same quarter last year, the firm earned $0.20 earnings per share. As a group, equities research analysts predict that Hims & Hers Health, Inc. will post 0.03 earnings per share for the current year.

Insider Buying and Selling at Hims & Hers Health

In other Hims & Hers Health news, CFO Oluyemi Okupe sold 7,163 shares of the business’s stock in a transaction on Monday, July 6th. The stock was sold at an average price of $36.49, for a total value of $261,377.87. Following the transaction, the chief financial officer owned 284,321 shares of the company’s stock, valued at approximately $10,374,873.29. The trade was a 2.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Irene Becklund sold 4,490 shares of the stock in a transaction on Wednesday, June 17th. The stock was sold at an average price of $31.50, for a total value of $141,435.00. Following the sale, the insider owned 6,790 shares in the company, valued at $213,885. The trade was a 39.80% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 83,126 shares of company stock worth $2,711,339 over the last 90 days. Company insiders own 11.76% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Binnacle Investments Inc acquired a new stake in Hims & Hers Health in the 3rd quarter valued at about $28,000. Versant Capital Management Inc raised its stake in shares of Hims & Hers Health by 801.2% in the second quarter. Versant Capital Management Inc now owns 748 shares of the company’s stock worth $26,000 after acquiring an additional 665 shares during the last quarter. MassMutual Private Wealth & Trust FSB lifted its position in shares of Hims & Hers Health by 70.0% during the second quarter. MassMutual Private Wealth & Trust FSB now owns 775 shares of the company’s stock worth $27,000 after purchasing an additional 319 shares in the last quarter. Silicon Valley Capital Partners acquired a new position in shares of Hims & Hers Health during the third quarter worth approximately $48,000. Finally, Flagship Harbor Advisors LLC bought a new stake in shares of Hims & Hers Health during the fourth quarter valued at approximately $28,000. Institutional investors and hedge funds own 63.52% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.